JP2022512974A5 - - Google Patents

Info

Publication number
JP2022512974A5
JP2022512974A5 JP2021525082A JP2021525082A JP2022512974A5 JP 2022512974 A5 JP2022512974 A5 JP 2022512974A5 JP 2021525082 A JP2021525082 A JP 2021525082A JP 2021525082 A JP2021525082 A JP 2021525082A JP 2022512974 A5 JP2022512974 A5 JP 2022512974A5
Authority
JP
Japan
Prior art keywords
synthesis
ifn
subject
pharmaceutical composition
repression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060285 external-priority patent/WO2020097344A1/en
Publication of JP2022512974A publication Critical patent/JP2022512974A/ja
Publication of JP2022512974A5 publication Critical patent/JP2022512974A5/ja
Pending legal-status Critical Current

Links

JP2021525082A 2018-11-08 2019-11-07 生体内crispr超抑制因子による合成免疫調節 Pending JP2022512974A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757679P 2018-11-08 2018-11-08
US62/757,679 2018-11-08
US201962899584P 2019-09-12 2019-09-12
US62/899,584 2019-09-12
PCT/US2019/060285 WO2020097344A1 (en) 2018-11-08 2019-11-07 Synthetic immunomodulation with a crispr super-repressor in vivo

Publications (2)

Publication Number Publication Date
JP2022512974A JP2022512974A (ja) 2022-02-07
JP2022512974A5 true JP2022512974A5 (cg-RX-API-DMAC7.html) 2023-06-12

Family

ID=70611555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525082A Pending JP2022512974A (ja) 2018-11-08 2019-11-07 生体内crispr超抑制因子による合成免疫調節

Country Status (10)

Country Link
US (2) US11884925B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877398A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022512974A (cg-RX-API-DMAC7.html)
KR (1) KR20210102247A (cg-RX-API-DMAC7.html)
CN (1) CN113330023A (cg-RX-API-DMAC7.html)
AU (1) AU2019375914A1 (cg-RX-API-DMAC7.html)
CA (1) CA3119302A1 (cg-RX-API-DMAC7.html)
IL (1) IL283022A (cg-RX-API-DMAC7.html)
SG (1) SG11202104802RA (cg-RX-API-DMAC7.html)
WO (1) WO2020097344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773407B2 (en) 2017-06-26 2023-10-03 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR logic circuits for safer and controllable gene therapies
WO2019005851A1 (en) 2017-06-26 2019-01-03 Arizona Board Of Regents On Behalf Of Arizona State University UNIVERSAL PLATFORM FOR ENHANCED CRISPR GENE EDITION FOR IN VIVO THERAPIES
WO2023288306A2 (en) * 2021-07-16 2023-01-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeting myd88 gene in vitro and in vivo
JP2025506744A (ja) * 2022-02-17 2025-03-13 シンタックス バイオ,インク. 細胞プログラミングのためのシステムおよびその方法
EP4711456A1 (en) * 2024-09-11 2026-03-18 GenCC GmbH & Co. KG Method for the manufacture of individualized crispr/cas complexes and individualized crispr/cas complexes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US20030148986A1 (en) * 2001-12-17 2003-08-07 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting myeloid differentiation factor 88
CN102166214B (zh) 2011-03-02 2012-12-12 华中科技大学同济医学院附属同济医院 氨基噻唑类MyD88特异性抑制剂在医学上的用途
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
JP2017506232A (ja) * 2014-02-07 2017-03-02 Sbiバイオテック株式会社 腫瘍を治療するための阻害性オリゴヌクレオチド
WO2016049258A2 (en) * 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3230452B1 (en) * 2014-12-12 2025-06-11 The Broad Institute, Inc. Dead guides for crispr transcription factors
EP3929287A3 (en) * 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
UA121890C2 (uk) 2015-07-08 2020-08-10 Рісерч Енд Бізнес Фаундейшн Сонгюнгван Юніверсіті Похідні карбоксамідопіролідину та способи їхнього отримання та застосування
JP7059179B2 (ja) 2015-10-20 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品
US11439692B2 (en) * 2017-05-17 2022-09-13 Modalis Therapeutics Corporation Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
US11773407B2 (en) * 2017-06-26 2023-10-03 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR logic circuits for safer and controllable gene therapies
WO2019018349A1 (en) * 2017-07-17 2019-01-24 Codiak Biosciences, Inc. NANOVESICLES PRODUCED FROM MESENCHYMAL STROMAL CELLS FOR ANTI-INFLAMMATORY APPLICATIONS
US11629342B2 (en) * 2017-10-17 2023-04-18 President And Fellows Of Harvard College Cas9-based transcription modulation systems

Similar Documents

Publication Publication Date Title
Lubyova et al. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors
Pryhuber et al. Tumor necrosis factor-alpha decreases surfactant protein B mRNA in murine lung
Yang et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury.
Oliff et al. Tumors secreting human TNF/cachectin induce cachexia in mice
ES2220929T3 (es) Inhibidor de la actividad il-6.
Rudders et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-κB to regulate the inducible nitric-oxide synthase gene
US5565334A (en) Enhancer sequence for modulating expression in epithelial cells
JP2021513863A5 (cg-RX-API-DMAC7.html)
JP2023543218A5 (cg-RX-API-DMAC7.html)
Zhao et al. Differential expression of caprine β-defensins in digestive and respiratory tissues
JP2021523696A5 (cg-RX-API-DMAC7.html)
Scherer et al. The human CMV IE1 protein: an offender of PML nuclear bodies
Dai et al. Fasudil exerts a cardio‐protective effect on mice with coxsackievirus B3‐induced acute viral myocarditis
CN110420331A (zh) Alkbh5抑制物在治疗病毒感染性疾病中的应用
JP2020503265A5 (cg-RX-API-DMAC7.html)
JP2013504603A5 (cg-RX-API-DMAC7.html)
Kim et al. Cloning and cell type-specific regulation of the human tyrosine hydroxylase gene promoter
Ishikawa et al. Phage ϕC31 integrase‐mediated genomic integration of the common cytokine receptor gamma chain in human T‐cell lines
Dekimpe et al. Toward gene therapy for congenital thrombotic thrombocytopenic purpura
JP2020517268A5 (cg-RX-API-DMAC7.html)
Roschke et al. Chromosomal translocations deregulating c-myc are associated with normal immune responses
JP6803619B2 (ja) REIC/Dkk−3遺伝子およびチェックポイント阻害剤を用いた併用療法
JP2024533314A5 (cg-RX-API-DMAC7.html)
Muraoka et al. Genomic structure of human BST-1
Dixon et al. Cloning a cDNA from human NK/T cells which codes for an unusual leucine zipper containing protein